Seems you still can't get your Sore head around the timing of...

Seems you still can't get your Sore head around the timing of stems in COVID-ARDS old bean.

You said: "by the time people are really sick, it’s too late to use stems because they don’t work unless taken at an early stage." This statement could not be further from the truth. During the early viral replication stage of COVID the infection is replicating and producing a viral response (this is where the antivirals/MAbs etc need to be taken early to prevent (treat) the early viral replication phase and response. It is not until the COVID infection is compromising the lungs after the early stage, more specifically at the pulmonary and hyperinflammation phases where Rem-L is best positioned to tackle the inflammation pathway which may progress to out of control inflammation via cytokine storm. This is after the early stage as you have stated, and yes Rem-L works in the under 65's population here just fine.

You said: "Although They are all effective, not 100% so." Yes this is stating the bleeding obvious. Hence why there will always be a place for Rem-L in treating patient that progress to COVID-ARDS (i.e. when the early stage therapies have failed).

You said: "US$70k a pop". Do you know for a fact that this will be the cost if we are granted an EUA? If so provide link, I must have missed the announcement.

You said: " So, who is going to be wildly injecting stems into a whole bunch of people who are not yet really sick, and who may never get really sick, at US$70k a pop". Well the simple answer is no one is going to be injecting stems into people who are not yet really sick because they do not present with symptoms of ARDS.

At best it seems you are confusing the different treatment options for the different phases of COVID. But we all really know why you write what you write.